You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Related Research Videos on Diabetes Health TV
Nuevas Pequeñas Molécula Drogas Para El Tipo 2 - Ensayos Humanos En Curso
Continuous Glucose Monitoring with DEXCOM's "The Seven"
Nipro Diabetes Systems Introduces The Amigo®
Popular Medications Research Articles
Highly Recommended Medications Research Articles
A new drug for type 2 diabetes started showing up in drugstores this week, according to manufacturer Santarus. The FDA-approved drug, called Cycloset, takes an distinctive -- and not well understood -- approach to reducing blood sugar levels. The pill apparently works by increasing dopamine activity in the hypothalamus, a part of the brain. Dopamine is a brain chemical that plays a big role in people's behavior, mood, and ability to sleep. Scientists theorize that glucose intolerance and insulin resistance may in part result from abnormal activity of this chemical, and that upping dopamine activity may iron out these problems.That's the theory, at least: the drug's exact workings aren't known. But it seems to do the trick.
0 comments - Nov 24, 2010 -
In a proof-of-concept study presented at the 2010 Annual Clinical Congress of the American College of Surgeons, the researchers note that the matrix not only helps to understand the micro-architecture of the pancreas, but also prolongs the survival and preserves the function of the islets. Islets survived longer in the bio-artificial matrix than in conventional transplantation sites, and they produced significantly more insulin when challenged with glucose.
0 comments - Oct 30, 2010 -
(Reuters) - Genetic testing might have helped identify people who would become depressed or suicidal while taking Sanofi-Aventis' weight loss drug Acomplia, which might have helped keep the drug on the market, U.S. researchers said on Thursday.
0 comments - Aug 19, 2010 -
"The objective of this clinical trial (research study) is to determine if the medications can rescue the few beta cells that remain soon after the diagnosis of type 1 diabetes; and whether new beta cells can even be regenerated," commented Alex Rabinovitch, MD, Principal Investigator of the trial and Associate Director of The Sanford Project. "The investigational combinations of these medications could possibly allow patients to decrease or no longer need to inject insulin to keep their blood levels under proper control."
0 comments - Aug 12, 2010 -
And wouldn't it be great if that pill weren't something advertised on late-night TV, but rather a legitimate treatment? A drug called rimonabant, introduced in Europe, seemed to fit the bill at first, but it was pulled from the market in late 2008 due to concerns about psychiatric side effects.
0 comments - Aug 10, 2010 -
Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.
0 comments - Aug 5, 2010 -
NEW YORK, NY, July 26, 2010 - Recalling the desperate fight for life that used to be waged by juvenile diabetes patients, and commemorating the events of 1921 that inaugurated a new era of hope for them and their families, the New York Historical Society will present the exhibition Breakthrough: The Dramatic Story of the Discovery of Insulin from October 5, 2010 through January 31, 2011. Exploring the roles of science, government, higher education and industry in developing and distributing a life-saving drug, the exhibition will bring to life the personalities who discovered insulin and raced to bring it to the world and will tell the story of one extraordinary New York girl-Elizabeth Evans Hughes, daughter of the leading statesman and jurist Charles Evans Hughes-who was among the very first patients to be saved.
0 comments - Jul 26, 2010 -
(Reuters) - The first new prescription weight-loss pill in more than a decade failed to win backing from U.S.health advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds.
0 comments - Jul 19, 2010 -
The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the scientific research available on the safety of rosiglitazone. The deliberations of the panel reflected the complexity of the issues, with several members voting to add additional warnings or to withdraw the drug from the U.S. market. Ultimately, the final recommendation was to allow Avandia to remain on the market. Now that the expert panel has concluded its meeting, the FDA will review their recommendations and make the final decision on whether the drug remains available to patients.
0 comments - Jul 15, 2010 -
Having discovered a dramatic increase of an easy-to-detect enzyme in the red blood cells of people with diabetes and pre-diabetes, Johns Hopkins scientists say the discovery could lead to a simple, routine test for detecting the subtle onset of the disease, before symptoms or complications occur and in time to reverse its course.
0 comments - Jul 15, 2010 -
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.